Juan Medina

Alright, listen up. Juan Medina? Dude’s the real deal. He’s a biotech nerd turned hardcore startup founder with a story that just hits different. So, he kicked things off with a solid engineering background, studied bioengineering at Escuela de Ingeniería de Antioquia, then took it to the next level with a master’s at NYU in Applied Urban Science and Informatics. The guy’s been geeky from day one, but what’s crazy is how he jumped from academia into the trenches of cancer research and tech.

He did stints at Mayo Clinic and Memorial Sloan Kettering, which are no joke, top-tier places. He was deep in the lab, working on cancer stuff, really understanding how complex and fucked up the disease is. But here’s where it gets interesting: he didn’t just stay in research. No, he jumped into building something that could actually change lives. That’s how Isabl was born in 2020, right in the middle of the W20 YC batch. He co-founded it with Andrew Kung and Elli Papaemmanuil, and bam, they’re tackling cancer diagnostics head-on using whole genome and transcriptome data.

What makes Juan different? It’s his hustle and vision. He saw that data is the key to personalized cancer treatment. Instead of just studying cancer, he’s building tech that analyzes a person’s entire genome to find exactly what’s going wrong. That’s some advanced shit, precision diagnostics, disease monitoring, biomarker discovery. He’s not just doing research for paper’s sake; he’s turning it into tools that can actually save lives.

And let’s talk motivation. This guy’s been through the grind, big research labs, hospitals, then jumping into YC and starting his own thing. It’s clear he’s driven by a desire to make a real impact, to take the complex science he’s passionate about and turn it into something expandable and practical. Starting Isabl wasn’t just about tech, it’s about fighting cancer smarter, faster, better.

So, Juan Medina is basically the embodiment of a scientist who said, “Fuck waiting around,” and then built a company that’s pushing the boundaries of cancer care. He’s proof that with enough hustle and smarts, you can turn deep science into real-world solutions. The dude’s not just a founder; he’s a big change in biotech. And honestly? No Cap, he’s just getting started.